Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Date:12/4/2007

NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq Capital Market: VION) today announced the start of an investigator-sponsored Phase I clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with hematopoietic cell transplant (HCT) in patients with various advanced hematologic malignancies. The trial is being conducted under the direction of Roy Jones, M.D., Ph.D., a professor in the Department of Stem Cell Transplantation at The University of Texas M.D. Anderson Cancer Center.

The objective of the trial is to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given to patients of 18 to 65 years of age with poor-prognosis leukemia, lymphoma, and Hodgkin's disease who are undergoing either an allogeneic or autologous HCT.

Ann Cahill, Vice President of Clinical Development, commented, "Both patients and physicians are searching for ways to improve outcomes after stem cell transplantation. Patients with advanced disease are particularly in need of new therapies." Ms. Cahill concluded, "We are hopeful that Cloretazine(R) (VNP40101M) can make a contribution in the stem cell transplant setting."

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials spon
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 5, 2015  In line with CBME China,s 15 ... community with a charity program to create awareness, draw ... CBME China team is coordinating a donation ... manufacturers, brand owners and distributors. All donated products will ... Proceeds from the sale will be used to support ...
(Date:5/5/2015)... 2015  CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical ... the treatment of infectious diseases, announced that it will ... Randy Milby , Chief Executive Officer of CorMedix, ... 8 at 9:00 a.m. EDT.  In ... 1-877-407-8031 (U.S.), 1-201-689-8031 (outside the U.S.). All participants who ...
(Date:5/5/2015)... 2015   Temptime Corporation , the world,s leading ... announced today that its board of directors has promoted ... executive officer.  Mr. Van den Hooff , 56, ... "Renaat deeply values Temptime,s mission of improving global ... Temptime,s products and services to organizations that are saving ...
Breaking Medicine Technology:CBME China Launches Charity Program to Support Children with Autism 2CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015 2Temptime President Renaat Van den Hooff Promoted to CEO 2
... Conn., Feb. 28, 2012 /PRNewswire-iReach/ --  Silver ... New Canaan, CT, announces the opening of the Chronic ... for patients with pain who have become addicted to ... American Pain Society, is the Medical Director. ...
... Crothall Healthcare announced the name change of its ... Solutions (CES). The new name emphasizes Crothall,s intent to ... of healthcare technology rather than the traditional "fix it" ... CES division will continue to focus on safety, risk ...
Cached Medicine Technology:Silver Hill Hospital, Nationally Recognized Psychiatric Institution Opens Groundbreaking Chronic Pain and Addiction Treatment Center 2Silver Hill Hospital, Nationally Recognized Psychiatric Institution Opens Groundbreaking Chronic Pain and Addiction Treatment Center 3Crothall Healthcare Introduces Clinical Equipment Solutions Division 2
(Date:5/6/2015)... Hope For The Warriors® and American ... at the New York Athletic Club on April 21, ... The Warriors®, a national nonprofit dedicated to restoring a ... hope for our service members and our military families. ... local and nationwide military families. The Barry Fixler Foundation/Semper ...
(Date:5/6/2015)... Wethersfield, Conn. (PRWEB) May 06, 2015 ... company in Wethersfield, Conn., has hired healthcare executive ... vice president. Olson will lead Qualidigm’s growing ... further Qualidigm’s mission to improve the quality, safety, ... Olson comes to Qualidigm from Interim HealthCare of ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Doctors who ... reported what they are calling “unprecedented” tumor control in ... on the new research. Click here to read ... pembrolizumab to 25 mesothelioma patients between March and December ... in April. , “Pembrolizumab… provides robust antitumor activity in ...
(Date:5/6/2015)... Stout Industries is owned and operated ... Austin, Texas fire departments. Stout Industries recently developed Fire-ground ... components to these fire safety devices. The departure lights ... is turned on. They light the area within 50 feet ... on the roof, preventing leg and ankle injuries. In ...
(Date:5/6/2015)... 2015 Spiking drug prices are taking large ... survey by The Senior Citizens League (TSCL). ... co-pays and co-insurance costs than expected in 2014 according to ... cost spikes may be tough for many beneficiaries to figure ... prices are commonly associated with brand and newer specialty drugs, ...
Breaking Medicine News(10 mins):Health News:4th Annual Casino Night Draws Support for Military Families in New York City Region 2Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 2Health News:Innovative Healthcare Executive Ann Olson Joins Qualidigm as Principal and Vice President 3Health News:Researchers Say “Unprecedented” Mesothelioma Response Possible with Skin Cancer Drug, According to Surviving Mesothelioma 2Health News:Kickstarter for FIRE Lights, the New Fire Safety Devices 2Health News:New Survey By The Senior Citizens League Reveals 61% Had Higher Than Expected Medicare Part D Costs In 2014 2Health News:New Survey By The Senior Citizens League Reveals 61% Had Higher Than Expected Medicare Part D Costs In 2014 3
... of an effort to make high-precision particle cancer therapy ... Department of Energy,s (DOE) Brookhaven National Laboratory has developed ... beams. Brookhaven Science Associates, the company that manages the ... patent on the design, which is now available for ...
... A new study provides doctors with guidelines on when ... patients. , International clinical guidelines on the ... countries. For a serious condition like osteoporosis, affecting millions, ... Tuan Nguyen and Dr Nguyen Nguyen from the Garvan ...
... $5 Million Effort Aimed at Building Public Health Workforce ... The University of California, Berkeley , announced today the ... to meet the increasing need for highly educated public health ... established in 2004 by Kaiser Permanente at the East Bay ...
... of diabetes treatments, local gyms and fresh food among ... implementing healthy habits to take control of their diabetes ... Diabetes (TCOYD), a not-for-profit organization dedicated to informing and ... their own health care, announced findings today from a ...
... is a Leader in Supporting the CommunityPORTLAND, Ore., May ... men and women, is actively involved in keeping Portland ... to raise money for charitable auctions, making cash donations ... food drives for women,s and children,s shelters, partnering with ...
... Nationwide locations open doors to professionals and families caring ... May 12 Sunrise Senior Living (NYSE: ... of HBO,s The Alzheimer,s Project to encourage ... the numerous issues surrounding it. Locate a local ...
Cached Medicine News:Health News:Compact cancer-therapy particle-delivery system patented 2Health News:When to get your bone density measured -- that is the question 2Health News:UC Berkeley Launches Kaiser Permanente Community Health Scholars Program 2Health News:UC Berkeley Launches Kaiser Permanente Community Health Scholars Program 3Health News:Indianapolis Residents View Economic Challenges as Significant Barrier to Properly Managing Type 2 Diabetes 2Health News:Indianapolis Residents View Economic Challenges as Significant Barrier to Properly Managing Type 2 Diabetes 3Health News:Indianapolis Residents View Economic Challenges as Significant Barrier to Properly Managing Type 2 Diabetes 4Health News:Bishops Barbershop - Keeping Portland a Great Place to Live 2Health News:Sunrise Senior Living Communities to Show HBO's The Alzheimer's Project 2Health News:Sunrise Senior Living Communities to Show HBO's The Alzheimer's Project 3
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
... Processor is a primary component of an ... processing, sampling, and slide preparation all ... MonoPrep LBP Processor produces high-quality sample slides ... range of cytology specimen types. It processes ...
... Binding, Graduated Pipet Tips - 2l - 200l. ... referenced. Produced & packaged completely by automation. RNAse ... packaged 96 tips/rack and 10 racks/cs. AVR2 is ... racks/cs. AVR3 is the Stacked Rack packaged 96 ...
Medicine Products: